|
|
|
| Effects of Propranolol Combined with Methimazole on Serum PTH OCN ALP Ca and P Levels of Patients with Hyperthyroidism |
| XU Wen, CHEN Chaocong, XU Wenjuan |
| Danzhou People's Hospital, Hainan Danzhou 571700, China |
|
|
|
|
Abstract Objective: To analyze the effects of propranolol combined with methimazole on serum parathyroid hormone (PTH), osteocalcin (OCN), alkaline phosphatase (ALP), calcium (Ca) and phosphorus (P) levels in patients with hyperthyroidism. Methods: A total of 200 patients with hyperthyroidism who were admitted to the hospital from December 2017 to December 2018 were selected as subjects. They were divided into the observation group (n=100) and the control group (n=100) with simple random method. The control group was treated with methimazole while the observation group was treated with propranolol combined with methimazole. The clinical curative effect, serum PTH, OCN, ALP, Ca and P levels, the incidence of adverse reactions and recurrence rate were compared between the two groups. Results: After treatment, the levels of serum PTH and Ca in the observation group were significantly higher than those in the control group. The levels of OCN, ALP and P were significantly lower than those in the control group (P<0.05). The total effective rate of the observation group after treatment was significantly higher than that of the control group (88.00% vs 70.00%) (P<0.05). The incidence of adverse reactions in the observation group after treatment was significantly lower than that in the control group (6.67% vs 24.44%) (P<0.05).The recurrence rate of the observation group was 3.00%, which was significantly lower than that of the control group (11.00%) (P<0.05). Conclusion: The clinical curative effect of propranolol combined with methimazole is obvious in the process of hyperthyroidism treatment. The comprehensive treatment can reduce the levels of serum OCN, ALP and P, and increase the levels of PTH and Ca.
|
|
|
|
|
|
[1] 钟筑宁, 罗丽丽, 肖文革, 等.关于甲亢患者肝功能异常的临床观察[J].贵州医药, 2017, 41(3):289~290.
[2] 庞雅玲, 王养维, 李辉, 等.2型糖尿病合并甲亢患者脂肪因子及氧化应激状态评估[J].陕西医学杂志, 2016, 45(7):819~821.
[3] 吴佩娴, 张帆, 蓝薇, 等.药物治疗对初诊甲亢患者骨密度和骨代谢标记物的影响[J].热带医学杂志, 2016, 10(11):1399~1401.
[4] 彭雪萍.甲亢患者康复期血清甲状旁腺激素和骨代谢指标水平的变化及其临床意义[J].现代医学, 2016, 44(9):1250~1254.
[5] 王萍, 何晓俐, 何谦, 等.甲巯咪唑联合普萘洛尔治疗轻中度甲状腺功能亢进症患者甲状腺功能、血清COR及ACTH水平的变化[J].临床误诊误治, 2019, 32(6):33~36.
[6] 张幽幽, 高钱钢, 杨宏伟, 等.^131I联合丙硫氧嘧啶治疗对甲亢患者血清CT、PTH、BGP水平及甲状腺功能的影响[J].中国药师, 2016, 19(12):2272~2274.
[7] 刘祥秀, 孔德明, 代芳, 等.养阴清肝散结方联合西药治疗阴虚火旺型Graves病患者的临床疗效观察及其机制研究[J].中国医院药学杂志, 2017, 37(10):968~971.
[8] 胡金娥.普萘洛尔联合甲巯咪唑治疗甲状腺功能亢进的效果观察[J].白求恩医学杂志, 2019, 17(3):237~238.
[9] 刘祥秀, 孔德明, 代芳, 等.养阴消瘿方联合西药治疗Graves病的临床疗效分析[J].重庆医学, 2017, 46(29):4060~4062.
[10] 胡文华, 王伟伟.甲巯咪唑联合左旋甲状腺素治疗Graves病78例临床疗效[J].医学临床研究, 2017, 34(10):2016~2018. |
|
|
|
2020, Vol. 26 
